IP Library Granted Patent US 8,859,534
Granted Patent B2
US 8,859,534 · App. 13/758,098 · Granted Oct 14, 2014

2-carboxamide-7-piperazinyl-benzofuran derivatives

Inventors: Johan Andersson (Sodertalje, SE); Helena Gyback (Sodertalje, SE); Anh Johansson (Sodertalje, SE); Christian Erik Linde (Sodertalje, SE); Jonas Malmstrom (Sodertalje, SE); Gunnar Nordvall (Sodertalje, SE); Tatjana Weigelt (Sodertalje, SE); Gitte Terp (Sodertalje, SE)
Assignee: Acturum Life Science AB
C07D405/12C07D307/84C07D307/85C07D407/14C07D417/14C07D413/14C07D405/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,859,534
App. No.
13/758,098
Granted
Oct 14, 2014
Kind
B2
Abstract

The present invention relates to compounds of formula (I), wherein R 1 is heteroaryl or heterocyclyl, optionally substituted; R 2 is C 1-4 alkyl, heterocyclyl, C 1-4 alkylaryl, C 1-4 alkylheteroaryl, carbocyclyl, C 1-4 alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R 3 is hydrogen or C 1-4 alkyl, or R 2 and R 3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R 4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.

Claims (85)

1. A compound of formula (I),

wherein

R 1 is pyridinyl or indolinyl, wherein said pyridinyl or indolinyl is optionally substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, halogen, CF 3 , CN, C 1-4 alkoxy, —C(O)C 1-4 alkyl, —NC 1-4 alkylC(O)C 1-4 alkyl, —NHC(O)C 1-4 alkyl, —C(O)HN(C 1-4 alkyl) and —C(O)N(C 1-4 alkyl) 2 ;

R 2 is C 1-4 alkyl, heterocyclyl, —C 1-4 alkyl-phenyl, —C 1-4 alkylheteroaryl, carbocyclyl, —C 1-4 alkylheterocyclyl, -heterocyclyl-heteroaryl, -phenyl-heterocyclyl, -carbocyclyl-heteroaryl, -heterocyclyl-phenyl, wherein in said groups the heterocyclyl, phenyl, heteroaryl or carbocyclyl moiety may be optionally substituted with one or more substituents selected from the group consisting of halogen, C 1-4 alkoxy, —C(O)C 1-4 alkyl, —C 0-4 alkylSO 2 C 1-4 alkyl, cyano, hydroxy, and —C 1-4 alkyl;

R 3 is hydrogen or C 1-4 alkyl, or

R 2 and R 3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms selected from carbon or nitrogen and wherein said ring system is optionally substituted with one or more substituent selected from halogen, C 1-4 alkyl and C 1-4 alkoxy, —O-heteroaryl;

R 4 is hydrogen, halogen, methyl or methoxy;

wherein

heteroaryl is a monocyclic aromatic heterocycle containing 1 or 2 heteroatoms that are each independently nitrogen, sulphur, or oxygen; or benzodioxolyl; and

heterocyclyl is a saturated monocyclic ring containing 3 to 7 atoms of which 1 or 2 ring atoms are each independently nitrogen, sulphur, or oxygen;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein R 1 is indolinyl.

3. The compound according to claim 1 , wherein R 1 is pyridinyl.

4. The compound according to claim 1 , wherein R 2 is —C 1-4 alkylheteroaryl and wherein said heteroaryl is pyridinyl, pyrimidinyl, imidazolyl, pyrazolyl or benzodioxolyl.

5. The compound according to claim 1 , wherein R 2 and R 3 are C 1-4 alkyl.

6. The compound of formula (I),

wherein

R 1 is pyridine-2-yl;

R 2 is C 1-4 alkyl, heterocyclyl, —C 1-4 alkyl-phenyl, —C 1-4 alkylheteroaryl, carbocyclyl, —C 1-4 alkylheterocyclyl, -heterocyclyl-heteroaryl, -phenyl-heterocyclyl, -carbocyclyl-heteroaryl, heterocyclyl-phenyl, or -heterocyclyl-O-heteroaryl, wherein said groups the heterocyclyl, phenyl, heteroaryl or carbocyclyl moiety may be optionally substituted with one or more substituents selected from the group consisting of halogen, C 1-4 alkoxy, —C(O)C 1-4 alkyl, —C 0-4 alkylSO 2 C 1-4 alkyl, cyano, hydroxy, and C 1-4 alkyl;

R 3 is hydrogen or C 1-4 alkyl, or

R 2 and R 3 may together with the nitrogen atom, form a saturated ring system containing 4 or 5 or 6 ring forming atoms selected from carbon or nitrogen;

R 4 is hydrogen,

wherein

heteroaryl is a monocyclic aromatic heterocycle containing 1 or 2 heteroatoms that are each independently nitrogen, sulphur, or oxygen; or benzodioxolyl; and

heterocyclyl is a saturated monocyclic ring containing 3 to 7 atoms of which 1 or 2 ring atoms are each independently nitrogen, sulphur, or oxygen;

or a pharmaceutically acceptable salt thereof.

7. The compound of formula (I) according to claim 1 , wherein

R 1 is pyridine-2-yl;

R 2 and R 3 are C 1-4 alkyl;

R 4 is hydrogen, or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 , which is

7-(4-(2-(Pyridin-2-yl)ethyl)piperazin-1-yl)-N-(pyridin-2-ylmethyl)benzofuran-2-carboxamide;

N-(4-Morpholinophenyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(1-Phenylpiperidin-4-yl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(4-(Methylsulfonyl)benzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-((1 -Methyl-1H-imidazol-4-yl)methyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1 -yl)benzofuran-2-carboxamide;

N-(1 -Acetylpiperidin-4-yl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(1-(Pyridin-2-yl)ethyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(1-(3-Chloropyridin-2-yl)piperidin-4-yl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(4-Cyanobenzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(Benzo [d][1,3]dioxol5-ylmethyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-Methyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-Cyclopropyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(3,3-Difluorocyclobutyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

Azetidin-1-yl(7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-yl)methanone;

(7-(4-(2-(Pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-yl)(pyrrolidin-1-yl)methanone;

N-(4-(Methylsulfonylmethyl)benzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(3-Methoxyphenethyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-Methyl-N-(3-(methylsulfonyl)benzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-((6-Cyanopyridin-3-yl)methyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-Methyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)-N-(pyridin-3-ylmethyl)benzofuran-2-carboxamide;

N-(3 -Cyanobenzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin- 1 -yl)benzofuran-2-carboxamide;

(7-(4-(2-(Pyridin-2-yl)ethyl)piperazin- 1-yl)benzofuran-2-yl)(4-(thiazol-2-yl)piperazin- 1 1-yl)methanone;

N-(1-(3-Methoxypyridin-2-yl)piperidin-4-yl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-Methyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin- 1 -yl)-N-(pyridin-2-ylmethyl)benzofuran-2-carboxamide;

N-(3 -Methoxybenzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin- 1 -yl)benzofuran-2-carboxamide;

N-(1 -(Pyridin-2-yl)cyclopropyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1 -yl)benzofuran-2-carboxamide;

N-(4-Methoxybenzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin- 1-yl)benzofuran-2-carboxamide;

N-(2-(4-Methylpyrimidin-2-yl)ethyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin- 1-yl)benzofuran-2-carboxamide;

N-(2-(1-Methyl-1H-imidazol-4-yl)ethyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

7-(4-(2-(Pyridin-2-yl)ethyl)piperazin- 1-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)benzofuran-2-carboxamide;

N-(1-(1-Methyl-1H-pyrazol-5-yl)ethyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-(1-(6-Methylpyridin-3-yl)ethyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

N-((2-Methylpyrimidin-5-yl)methyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

7-(4-(2-(Pyridin-2-yl)ethyl)piperazin-1-yl)-N-(pyridin-3-ylmethyl)benzofuran-2-carboxamide;

(7-(4-(2-(Pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-yl)(3-(pyridin-3-yloxy)azetidin-1-yl)methanone;

N-(3-Hydroxybenzyl)-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

7-(4-(2-(4-Methoxypyridin-2-yl)ethyl)piperazin-1-yl)—N,N-dimethylbenzofuran-2-carboxamide;

N,N-dimethyl-7-(4-(2-(5-methylpyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

7-(4-(2-(4-Cyanopyridin-2-yl)ethyl)piperazin-1-yl)—N,N-dimethylbenzofuran-2-carboxamide;

N,N-Dimethyl-7-(4-(2-(6-(trifluoromethyl)pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

7-(4-(2-(5-Acetylpyridin-2-yl)ethyl)piperazin-1-yl)-N,N-dimethylbenzofuran-2-carboxamide;

7-(4-(2-(5-Acetamidopyridin-2-yl)ethyl)piperazin-1-yl)-N,N-dimethylbenzofuran-2-carboxamide;

Azetidin-1-yl(7-(4-(2-(6-methoxypyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-yl)methanone;

7-(4-(2-(6-Methoxypyridin-2-yl)ethyl)piperazin-1-yl)-N,N-dimethylbenzofuran-2-carboxamide;

7-(4-(2-(5-Fluoropyridin-2-yl)ethyl)piperazin-1-yl)-N,N-dimethylbenzofuran-2-carboxamide;

7-(4-(2-(3-Methoxy-2-pyridyl)ethyl)piperazin-1-yl)-N,N-dimethylbenzofuran-2-carboxamide;

1-(5-(2-(4-(2-(Azetidine-1-carbonyl)benzofuran-7-yl)piperazin-1-yl)ethyl)indolin-1-yl)ethanone;

5-Fluoro-N,N-dimethyl-7-(4-(2-pyridin-2-yl)piperazin-1-yl)benzofuran-2-carboxamide;

7-(4-(2-(1-Acetylindolin-5-yl)ethyl)piperazin- 1-yl)-5 -fluoro-N,N-dimethylbenzofuran-2-carboxamide;

5-Methoxy-N,N-dimethyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide and

4-Bromo-N,N-dimethyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide; or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound of formula (I) according to claim 1 in association with a pharmaceutically acceptable excipient, carrier or diluent.

10. A method of treating bipolar depression or Major Depressive Disorders (MDD) comprising administering to a patient in need of such a treatment, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 .

11. A method of treating depression or major depression comprising administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ASTRAZENECA AB
To: ACTURUM LIFE SCIENCE AB
Reel/Frame 049674/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ACTURUM LIFE SCIENCE AB
To: ACTURUM REAL ESTATE AB
Reel/Frame 049674/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ACTURUM REAL ESTATE AB
To: ACTURUM LIFE AB
Reel/Frame 049675/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2013
From: JOHANSSON, ANH; ANDERSSON, JOHAN; GYBACK, HELENA; LINDE, ERIK CHRISTIAN; NORDVALL, GUNNAR; MALMSTROM, JONAS; WEIGELT, TATJANA; TERP, GITTE
To: ASTRAZENECA AB
Reel/Frame 030542/0320 →
Continuity (3)
Continuation 12824567 · Jun 28, 2010
Provisional Application 61221657 · Jun 30, 2009
Related Publication 20130296296A1 · Nov 7, 2013